NORTHERA

NORTHERA (droxidopa) is an oral capsule medication approved in February 2014 for treating orthostatic dizziness and lightheadedness associated with several autonomic nervous system disorders, including multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. It is a synthetic amino acid analog that is metabolized to norepinephrine by dopa-decarboxylase, exerting its effects through norepinephrine-mediated peripheral arterial and venous vasoconstriction to increase blood pressure. NORTHERA addresses an unmet need in a rare disease population where blood pressure management in standing positions is critically impaired, and represents one of few pharmacological options for symptomatic relief in these conditions.